- Home
- AGIO vs AHCO Comparison
AGIO vs AHCO Comparison
Compare AGIO & AHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- AHCO
- Stock Information
- Founded
- AGIO 2007
- AHCO 2012
- Country
- AGIO United States
- AHCO United States
- Employees
- AGIO N/A
- AHCO N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- AHCO Medical/Nursing Services
- Sector
- AGIO Health Care
- AHCO Health Care
- Exchange
- AGIO Nasdaq
- AHCO Nasdaq
- Market Cap
- AGIO 1.4B
- AHCO 1.2B
- IPO Year
- AGIO 2013
- AHCO N/A
- Fundamental
- Price
- AGIO $27.32
- AHCO $8.58
- Analyst Decision
- AGIO Buy
- AHCO Strong Buy
- Analyst Count
- AGIO 8
- AHCO 5
- Target Price
- AGIO $56.00
- AHCO $13.60
- AVG Volume (30 Days)
- AGIO 524.5K
- AHCO 2.0M
- Earning Date
- AGIO 05-01-2025
- AHCO 05-06-2025
- Dividend Yield
- AGIO N/A
- AHCO N/A
- EPS Growth
- AGIO N/A
- AHCO N/A
- EPS
- AGIO 11.45
- AHCO 0.58
- Revenue
- AGIO $37,035,000.00
- AHCO $3,246,360,000.00
- Revenue This Year
- AGIO $40.62
- AHCO $2.21
- Revenue Next Year
- AGIO $216.26
- AHCO $4.83
- P/E Ratio
- AGIO $2.39
- AHCO $14.84
- Revenue Growth
- AGIO 25.96
- AHCO N/A
- 52 Week Low
- AGIO $23.42
- AHCO $7.11
- 52 Week High
- AGIO $62.58
- AHCO $11.90
- Technical
- Relative Strength Index (RSI)
- AGIO 41.34
- AHCO 47.93
- Support Level
- AGIO $27.78
- AHCO $7.95
- Resistance Level
- AGIO $31.55
- AHCO $9.15
- Average True Range (ATR)
- AGIO 1.38
- AHCO 0.47
- MACD
- AGIO -0.03
- AHCO 0.10
- Stochastic Oscillator
- AGIO 2.98
- AHCO 69.25
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About AHCO AdaptHealth Corp.
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.